Loading...
Market
What will be the impact on ACA's no-cost HIV drugs coverage post-Supreme Court ruling by mid-2026?
2
Resolution / Starting Odds
No change • 25%
Partial coverage introduced • 25%
Full cost-sharing introduced • 25%
Coverage removed • 25%
Official ruling published by the U.S. Supreme Court or subsequent policy announcements
Story
Supreme Court to Review ACA's No-Cost Coverage for Cancer Screenings, Heart Statins, and HIV Drugs
Jan 10, 2025, 11:26 PM
The U.S. Supreme Court has agreed to review a challenge to the Affordable Care Act's (ACA) requirement for no-cost coverage of certain preventive care services, including cancer screenings, heart statins, and HIV drugs. The case, Braidwood Management, Inc. et al. v. Xavier Becerra, questions the constitutionality of the U.S. Preventive Services Task Force's authority to mandate such coverage. The challenge stems from a ruling by the 5th U.S. Circuit Court of Appeals, which found that the task force's structure violated the Appointments Clause of the U.S. Constitution because its members are not appointed by the president and confirmed by the Senate. The Supreme Court's decision to hear the case could impact the availability of these preventive services, which are currently covered without cost-sharing under the ACA.
View original story
Similar markets
Other • 25%
Remand to lower court for further proceedings • 25%
Strike down ACA coverage as unconstitutional • 25%
Uphold ACA coverage as constitutional • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Decrease in states restricting funding • 25%
No significant change • 25%
Increase in states restricting funding • 25%
Mixed outcomes • 25%
Increase to over 25 million • 25%
Other outcomes • 25%
Decrease below 23 million • 25%
Remain around 24 million • 25%
Significant expansion of rights • 25%
Significant restriction of rights • 25%
Minimal impact • 25%
Unclear impact • 25%
Allowed to expire • 25%
Extended as is • 25%
Replaced by new measures • 25%
Other outcomes • 25%
No changes • 25%
Major repeal efforts • 25%
Other outcomes • 25%
Minor adjustments • 25%
No change in similar bans • 25%
Increase in similar bans • 25%
Mixed changes • 25%
Decrease in similar bans • 25%
No • 50%
Yes • 50%
No significant change in availability • 25%
Increase in availability • 25%
Other • 25%
Decrease in availability • 25%
Mixed impact • 25%
Increase in similar laws • 25%
Decrease in similar laws • 25%
No change • 25%